Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3815269 | 0.91 | NSD2 (0.45) | NSD2KMT2AMEN1KDM1AMAPT | |
| SCHEMBL13839364 | 0.87 | NSD2 (0.46) | NSD2KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3811770 | 0.86 | KMT2A (0.45) | NSD2KMT2AMEN1KDM1AATM | |
| SCHEMBL3815252 | 0.85 | HDAC1 (0.51) | KMT2AMEN1ATMALDH1A1HTT | |
| SCHEMBL3815228 | 0.81 | NSD2 (0.47) | NSD2KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3814572 | 0.79 | NSD2 (0.42) | NSD2KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3818210 | 0.79 | KMT2A (0.45) | NSD2KMT2AMEN1KDM1AATM | |
| SCHEMBL3813361 | 0.78 | NSD2 (0.49) | NSD2KMT2AMEN1ACACBALDH1A1 | |
| SCHEMBL3811232 | 0.77 | CNR2 (0.45) | NSD2KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3809057 | 0.75 | HDAC1 (0.52) | KMT2AMEN1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | claimed |
| EP-1948190-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | claimed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| EP-1948190-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD11B2, HSD3B1 | NSD2 630/4885KMT2A 2957/4885MEN1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.